MEI Pharma Inc (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced updated results from a Phase II study of its investigational drug candidate Pracinostat in combination with azacitidine (marketed as Vidaza®) in elderly patients with newly diagnosed acute myeloid leukemia (AML). Data from 50 patients treated at 15 centers are being presented at the European Hematology Association (EHA) Annual Congress in Vienna. A copy of the poster, entitled “Updated Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia,” is now available at

To date, 27 of 50 patients (54%) have achieved the primary endpoint of complete response (CR) plus complete response with incomplete blood count recovery (CRi) plus morphologic leukemia-free state (MLFS), including 16 patients (32%) who achieved a CR. The response rate from this study compares favorably with previous studies of azacitidine alone in this population1. Most responses occur within the first two cycles and continue to improve with ongoing therapy.

Median overall survival has not yet been reached in the study, with 32 patients (64%) still being followed (range, 6-15 months). Survival of patients with intermediate-risk cytogenetic abnormalities appears greater than that for patients with high-risk cytogenetics, though neither subset of patients has reached median survival. The 60-day mortality rate, often used as a benchmark in AML clinical studies, was 10% (5 of 50).

Pracinostat in combination with azacitidine was well tolerated in this population of elderly AML patients. The most common treatment-emergent adverse events (AEs) included febrile neutropenia, thrombocytopenia, nausea and fatigue. AEs resulting in dose reductions were frequently due to disease under study. Nearly half of the patients (22 of 50) to date have received study drug beyond six months, reflecting long-term tolerability.

“The combination of Pracinostat and azacitidine continues to demonstrate compelling clinical activity in these elderly patients with newly diagnosed AML,” said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. “While the overall survival trend in this study is encouraging, we believe that longer follow-up is needed to gain an accurate survival estimate. Ultimately, this survival estimate will be critical in determining the development path forward for this combination. We look forward to providing an update when these data mature, which we expect to occur later this year.” (Original Source)

Shares of MEI Pharma closed yesterday at $1.98 . MEIP has a 1-year high of $8.33 and a 1-year low of $1.69. The stock’s 50-day moving average is $2.00 and its 200-day moving average is $3.69.

On the ratings front, MEI Pharma has been the subject of a number of recent research reports. In a report issued on March 24, Wells Fargo analyst Matthew J. Andrews downgraded MEIP to Hold, with a price target of $2.13, which implies an upside of 7.3% from current levels. Separately, on March 23, Cowen’s Boris Peaker reiterated a Buy rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Matthew J. Andrews and Boris Peaker have a total average return of -0.5% and 36.4% respectively. Andrews has a success rate of 14.3% and is ranked #2736 out of 3623 analysts, while Peaker has a success rate of 62.0% and is ranked #34.

In total, 2 research analysts have assigned a Hold rating and 2 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $2.50 which is 26.3% above where the stock closed yesterday.

MEI Pharma Inc is an oncology company focused on the clinical development of novel therapeutics for cancer. The Company operates in two geographic segments, the United States of America and Australia.